drug_type
RELEVANT_DRUG
intervention_type
monoclonal antibody (anti-GD2)
drug_description
Naxitamab, a humanized IgG1 anti-GD2 monoclonal antibody that binds GD2 on neuroblastoma cells and mediates ADCC and complement-dependent cytotoxicity.
nci_thesaurus_concept_id
C123428
nci_thesaurus_preferred_term
Naxitamab
nci_thesaurus_definition
A humanized monoclonal antibody directed against the human tumor-associated antigen GD2, with potential antineoplastic activity. Upon vaccination, naxitamab stimulates antibody-dependent cell-mediated cytotoxicity (ADCC) against GD2-expressing tumor cells. GD2, a disialoganglioside with expression in normal tissues restricted primarily to the cerebellum and peripheral nerves, is commonly expressed at high levels on tumors of neuroectodermal origins such as melanomas and neuroblastomas. Compared to the murine monoclonal antibody 3F8 (m3F8), the humanized form does not cause a human anti-mouse antibody (HAMA) response and shows enhanced ADCC activity.
drug_mesh_term
naxitamab
drug_category
CYTOTOXIC ANTIBODY
drug_class
General immune activator
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized IgG1 monoclonal antibody targeting the tumor-associated ganglioside GD2; binding to GD2 on neuroblastoma cells recruits immune effector functions to kill tumor cells via antibody‑dependent cell‑mediated cytotoxicity (ADCC) through FcγR‑bearing cells (e.g., NK cells, macrophages, granulocytes) and complement‑dependent cytotoxicity (CDC). No cytotoxic payload.
drug_name
DANYELZA
nct_id_drug_ref
NCT06528496